180 related articles for article (PubMed ID: 16682733)
1. Interpreting disparate responses to cancer therapy: the role of human population genetics.
Maitland ML; DiRienzo A; Ratain MJ
J Clin Oncol; 2006 May; 24(14):2151-7. PubMed ID: 16682733
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacogenetics of anticancer drugs].
de Chaisemartin L; Loriot MA
Pathol Biol (Paris); 2005 Mar; 53(2):116-24. PubMed ID: 15708657
[TBL] [Abstract][Full Text] [Related]
3. Genetic tests for predicting the toxicity and efficacy of anticancer chemotherapy.
Mladosievicova B; Carter A; Kristova V
Neoplasma; 2007; 54(3):181-8. PubMed ID: 17447847
[TBL] [Abstract][Full Text] [Related]
4. Somatic pharmacogenomics in cancer.
Ikediobi ON
Pharmacogenomics J; 2008 Oct; 8(5):305-14. PubMed ID: 18679398
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics for individualized cancer chemotherapy.
Efferth T; Volm M
Pharmacol Ther; 2005 Aug; 107(2):155-76. PubMed ID: 15890408
[TBL] [Abstract][Full Text] [Related]
6. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development.
Lee W; Lockhart AC; Kim RB; Rothenberg ML
Oncologist; 2005 Feb; 10(2):104-11. PubMed ID: 15709212
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics of colorectal cancer prevention and treatment.
Nguyen H; Tran A; Lipkin S; Fruehauf JP
Cancer Invest; 2006 Oct; 24(6):630-9. PubMed ID: 16982469
[TBL] [Abstract][Full Text] [Related]
8. The role of pharmacogenetics in chemotherapy: modulation of tumour response and host toxicity.
Boddy AV; Idle JR
Cancer Surv; 1993; 17():79-104. PubMed ID: 8137354
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology and pharmacogenetics of chemotherapeutic agents.
Dawood S; Leyland-Jones B
Cancer Invest; 2009 Jun; 27(5):482-8. PubMed ID: 19479485
[TBL] [Abstract][Full Text] [Related]
10. Using genetic variation to optimize cancer chemotherapy.
McLeod HL; Papageorgio C; Watters JW
Clin Adv Hematol Oncol; 2003 Feb; 1(2):107-11. PubMed ID: 16224389
[TBL] [Abstract][Full Text] [Related]
11. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.
Calvo E; Baselga J
J Clin Oncol; 2006 May; 24(14):2158-63. PubMed ID: 16682734
[TBL] [Abstract][Full Text] [Related]
12. CYP450 pharmacogenetics for personalizing cancer therapy.
van Schaik RH
Drug Resist Updat; 2008 Jun; 11(3):77-98. PubMed ID: 18486526
[TBL] [Abstract][Full Text] [Related]
13. [Genomic markers and anticancer chemotherapy].
Nishiyama M
Gan To Kagaku Ryoho; 2008 Feb; 35(2):194-9. PubMed ID: 18281756
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the pharmacogenetics of cancer chemotherapy.
Watters JW; McLeod HL
Curr Opin Mol Ther; 2002 Dec; 4(6):565-71. PubMed ID: 12596358
[TBL] [Abstract][Full Text] [Related]
16. Infusion of pharmacogenetics into cancer care.
Prows CA
Semin Oncol Nurs; 2011 Feb; 27(1):45-53. PubMed ID: 21255712
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomic discovery approaches: will the real genes please stand up?
Walgren RA; Meucci MA; McLeod HL
J Clin Oncol; 2005 Oct; 23(29):7342-9. PubMed ID: 16145062
[TBL] [Abstract][Full Text] [Related]
18. [Anticancer drug dosing--pharmacogenomic biomarkers or body surface area?].
Lehne G; Bjørheim J; Saeter G
Tidsskr Nor Laegeforen; 2007 Apr; 127(8):1040-4. PubMed ID: 17457389
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy.
Huang Y
Cancer Metastasis Rev; 2007 Mar; 26(1):183-201. PubMed ID: 17323126
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomic applications in clinical drug development.
Dracopoli NC
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S57-60. PubMed ID: 12856151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
